The company only recently announced plans for four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong.
Moderna currently has commercial subsidiaries in Italy, France, Germany, Spain, Switzerland, and the UK.
It also has several key manufacturing partnerships across Europe with CDMOs including Lonza in Switzerland and the Netherlands, ROVI in Spain, and Recipharm in France.
Moderna’s pipeline currently includes 40 development programs, of which 25 are in clinical trials.
The pharma group is looking to scale up the manufacturing and distribution of its COVID-19 vaccine while advancing other mRNA vaccine candidates and therapeutics to prevent and treat diseases with significant unmet needs across infectious diseases, immuno-oncology, rare and ultra-rare diseases, and autoimmune diseases.
Its goals include the plan to develop a pan-respiratory annual booster vaccine, with the idea of continuously customizing it. Moderna reckons such a broad annual single booster vaccine covering multiple viruses, such as COVID-19, influenza, and Respiratory Syncytial Virus could create value for the healthcare system through compliance, convenience for the customer, and a reduction in vaccine administration cost.
The company also intends to develop first-in-class vaccines against latent viruses for which there are no approved vaccines today. It has clinical candidates in development, in that respect, including Epstein-Barr Virus (P1), human immunodeficiency virus (P1), and Cytomegalovirus (P3).
“Latent viruses infect the body, lay dormant, and do not replicate but possess the capacity to activate, causing disease. In addition, new emerging evidence highlights that latent viral infections may have yet unknown negative effects.”